Cargando…

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans

BACKGROUND: Given the paucity of information on dose intensity, the objective of this study is to describe the use of adjuvant chemotherapy for stage III colon cancer, focusing on relative dose intensity (RDI), overall survival (OS) and disease-free survival (DFS). METHODS: Retrospective cohort of 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Aspinall, Sherrie L, Good, Chester B, Zhao, Xinhua, Cunningham, Francesca E, Heron, Bernadette B, Geraci, Mark, Passero, Vida, Stone, Roslyn A, Smith, Kenneth J, Rogers, Renee, Shields, Jenna, Sartore, Megan, Boyle, D Patrick, Giberti, Sherry, Szymanski, John, Smith, Doug, Ha, Allen, Sessions, Jolynn, Depcinski, Shawn, Fishco, Shane, Molina, Irvin, Lepir, Tanja, Jean, Carmela, Cruz-Diaz, Lymaris, Motta, Jessica, Calderon-Vargas, Rebeca, Maland, Janelle, Keefe, Sean, Tague, Marshall, Leone, Alice, Glovack, Brian, Kaplan, Blair, Cosgriff, Sean, Kaster, Lindsay, Tonnu-Mihara, Ivy, Nguyen, Kimmai, Carmichael, Jenna, Clifford, Linda, Lu, Kan, Chatta, Gurkamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352567/
https://www.ncbi.nlm.nih.gov/pubmed/25884851
http://dx.doi.org/10.1186/s12885-015-1038-y
_version_ 1782360481558691840
author Aspinall, Sherrie L
Good, Chester B
Zhao, Xinhua
Cunningham, Francesca E
Heron, Bernadette B
Geraci, Mark
Passero, Vida
Stone, Roslyn A
Smith, Kenneth J
Rogers, Renee
Shields, Jenna
Sartore, Megan
Boyle, D Patrick
Giberti, Sherry
Szymanski, John
Smith, Doug
Ha, Allen
Sessions, Jolynn
Depcinski, Shawn
Fishco, Shane
Molina, Irvin
Lepir, Tanja
Jean, Carmela
Cruz-Diaz, Lymaris
Motta, Jessica
Calderon-Vargas, Rebeca
Maland, Janelle
Keefe, Sean
Tague, Marshall
Leone, Alice
Glovack, Brian
Kaplan, Blair
Cosgriff, Sean
Kaster, Lindsay
Tonnu-Mihara, Ivy
Nguyen, Kimmai
Carmichael, Jenna
Clifford, Linda
Lu, Kan
Chatta, Gurkamal
author_facet Aspinall, Sherrie L
Good, Chester B
Zhao, Xinhua
Cunningham, Francesca E
Heron, Bernadette B
Geraci, Mark
Passero, Vida
Stone, Roslyn A
Smith, Kenneth J
Rogers, Renee
Shields, Jenna
Sartore, Megan
Boyle, D Patrick
Giberti, Sherry
Szymanski, John
Smith, Doug
Ha, Allen
Sessions, Jolynn
Depcinski, Shawn
Fishco, Shane
Molina, Irvin
Lepir, Tanja
Jean, Carmela
Cruz-Diaz, Lymaris
Motta, Jessica
Calderon-Vargas, Rebeca
Maland, Janelle
Keefe, Sean
Tague, Marshall
Leone, Alice
Glovack, Brian
Kaplan, Blair
Cosgriff, Sean
Kaster, Lindsay
Tonnu-Mihara, Ivy
Nguyen, Kimmai
Carmichael, Jenna
Clifford, Linda
Lu, Kan
Chatta, Gurkamal
author_sort Aspinall, Sherrie L
collection PubMed
description BACKGROUND: Given the paucity of information on dose intensity, the objective of this study is to describe the use of adjuvant chemotherapy for stage III colon cancer, focusing on relative dose intensity (RDI), overall survival (OS) and disease-free survival (DFS). METHODS: Retrospective cohort of 367 patients diagnosed with stage III colon cancer in 2003–2008 and treated at 19 VA medical centers. Kaplan-Meier curves summarize 5-year OS and 3-year DFS by chemotherapy regimen and RDI, and multivariable Cox proportional hazards regression was used to model these associations. RESULTS: 5-fluorouracil/leucovorin (FU/LV) was the most commonly initiated regimen in 2003 (94.4%) and 2004 (62.7%); in 2005–2008, a majority of patients (60%-74%) was started on an oxaliplatin-based regimen. Median RDI was 82.3%. Receipt of >70% RDI was associated with better 5-year OS (p < 0.001) and 3-year DFS (P = 0.009) than was receipt of ≤70% RDI, with 5-year OS rates of 66.3% and 50.5%, respectively and 3-year DFS rates of 66.1% and 52.7%, respectively. In the multivariable analysis of 5-year OS, oxaliplatin + 5-FU/LV (versus 5-FU/LV) (HR = 0.55; 95% CI = 0.34-0.91), >70% RDI at the first year (HR = 0.58; 95% CI = 0.37-0.89) and married status (HR = 0.66; 95% CI = 0.45-0.97) were associated with significantly decreased risk of death, while age ≥75 (versus 55–64) (HR = 2.06; 95% CI = 1.25-3.40), Charlson Comorbidity Index (HR = 1.17; 95% CI = 1.06-1.30), T4 tumor status (versus T1/T2) (HR = 5.88; 95% CI = 2.69-12.9), N2 node status (HR = 1.68; 95% CI = 1.12-2.50) and bowel obstruction (HR = 2.32, 95% CI = 1.36-3.95) were associated with significantly increased risk. Similar associations were observed for DFS. CONCLUSION: Patients with stage III colon cancer who received >70% RDI had improved 5-year OS. The association between RDI and survival needs to be examined in studies of adjuvant chemotherapy for colon cancer outside of the VA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1038-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4352567
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43525672015-03-09 Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans Aspinall, Sherrie L Good, Chester B Zhao, Xinhua Cunningham, Francesca E Heron, Bernadette B Geraci, Mark Passero, Vida Stone, Roslyn A Smith, Kenneth J Rogers, Renee Shields, Jenna Sartore, Megan Boyle, D Patrick Giberti, Sherry Szymanski, John Smith, Doug Ha, Allen Sessions, Jolynn Depcinski, Shawn Fishco, Shane Molina, Irvin Lepir, Tanja Jean, Carmela Cruz-Diaz, Lymaris Motta, Jessica Calderon-Vargas, Rebeca Maland, Janelle Keefe, Sean Tague, Marshall Leone, Alice Glovack, Brian Kaplan, Blair Cosgriff, Sean Kaster, Lindsay Tonnu-Mihara, Ivy Nguyen, Kimmai Carmichael, Jenna Clifford, Linda Lu, Kan Chatta, Gurkamal BMC Cancer Research Article BACKGROUND: Given the paucity of information on dose intensity, the objective of this study is to describe the use of adjuvant chemotherapy for stage III colon cancer, focusing on relative dose intensity (RDI), overall survival (OS) and disease-free survival (DFS). METHODS: Retrospective cohort of 367 patients diagnosed with stage III colon cancer in 2003–2008 and treated at 19 VA medical centers. Kaplan-Meier curves summarize 5-year OS and 3-year DFS by chemotherapy regimen and RDI, and multivariable Cox proportional hazards regression was used to model these associations. RESULTS: 5-fluorouracil/leucovorin (FU/LV) was the most commonly initiated regimen in 2003 (94.4%) and 2004 (62.7%); in 2005–2008, a majority of patients (60%-74%) was started on an oxaliplatin-based regimen. Median RDI was 82.3%. Receipt of >70% RDI was associated with better 5-year OS (p < 0.001) and 3-year DFS (P = 0.009) than was receipt of ≤70% RDI, with 5-year OS rates of 66.3% and 50.5%, respectively and 3-year DFS rates of 66.1% and 52.7%, respectively. In the multivariable analysis of 5-year OS, oxaliplatin + 5-FU/LV (versus 5-FU/LV) (HR = 0.55; 95% CI = 0.34-0.91), >70% RDI at the first year (HR = 0.58; 95% CI = 0.37-0.89) and married status (HR = 0.66; 95% CI = 0.45-0.97) were associated with significantly decreased risk of death, while age ≥75 (versus 55–64) (HR = 2.06; 95% CI = 1.25-3.40), Charlson Comorbidity Index (HR = 1.17; 95% CI = 1.06-1.30), T4 tumor status (versus T1/T2) (HR = 5.88; 95% CI = 2.69-12.9), N2 node status (HR = 1.68; 95% CI = 1.12-2.50) and bowel obstruction (HR = 2.32, 95% CI = 1.36-3.95) were associated with significantly increased risk. Similar associations were observed for DFS. CONCLUSION: Patients with stage III colon cancer who received >70% RDI had improved 5-year OS. The association between RDI and survival needs to be examined in studies of adjuvant chemotherapy for colon cancer outside of the VA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1038-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-18 /pmc/articles/PMC4352567/ /pubmed/25884851 http://dx.doi.org/10.1186/s12885-015-1038-y Text en © Aspinall et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Aspinall, Sherrie L
Good, Chester B
Zhao, Xinhua
Cunningham, Francesca E
Heron, Bernadette B
Geraci, Mark
Passero, Vida
Stone, Roslyn A
Smith, Kenneth J
Rogers, Renee
Shields, Jenna
Sartore, Megan
Boyle, D Patrick
Giberti, Sherry
Szymanski, John
Smith, Doug
Ha, Allen
Sessions, Jolynn
Depcinski, Shawn
Fishco, Shane
Molina, Irvin
Lepir, Tanja
Jean, Carmela
Cruz-Diaz, Lymaris
Motta, Jessica
Calderon-Vargas, Rebeca
Maland, Janelle
Keefe, Sean
Tague, Marshall
Leone, Alice
Glovack, Brian
Kaplan, Blair
Cosgriff, Sean
Kaster, Lindsay
Tonnu-Mihara, Ivy
Nguyen, Kimmai
Carmichael, Jenna
Clifford, Linda
Lu, Kan
Chatta, Gurkamal
Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
title Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
title_full Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
title_fullStr Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
title_full_unstemmed Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
title_short Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
title_sort adjuvant chemotherapy for stage iii colon cancer: relative dose intensity and survival among veterans
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352567/
https://www.ncbi.nlm.nih.gov/pubmed/25884851
http://dx.doi.org/10.1186/s12885-015-1038-y
work_keys_str_mv AT aspinallsherriel adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT goodchesterb adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT zhaoxinhua adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT cunninghamfrancescae adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT heronbernadetteb adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT geracimark adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT passerovida adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT stoneroslyna adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT smithkennethj adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT rogersrenee adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT shieldsjenna adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT sartoremegan adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT boyledpatrick adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT gibertisherry adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT szymanskijohn adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT smithdoug adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT haallen adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT sessionsjolynn adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT depcinskishawn adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT fishcoshane adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT molinairvin adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT lepirtanja adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT jeancarmela adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT cruzdiazlymaris adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT mottajessica adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT calderonvargasrebeca adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT malandjanelle adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT keefesean adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT taguemarshall adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT leonealice adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT glovackbrian adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT kaplanblair adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT cosgriffsean adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT kasterlindsay adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT tonnumiharaivy adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT nguyenkimmai adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT carmichaeljenna adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT cliffordlinda adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT lukan adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans
AT chattagurkamal adjuvantchemotherapyforstageiiicoloncancerrelativedoseintensityandsurvivalamongveterans